Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
NCT05064735 · View on ClinicalTrials.gov ↗
Study Summary
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study, participants will have talks with study staff about how to eat healthy food and how to be more physically active. The study will last for about 1 ½ years. Participants will have 14 clinic visits with the study staff. At the first clinic visit participants will have a blood sample taken. Participants will have an X-ray of participants knee taken at the first visit. If participants have had an X-ray recently, this may not be needed. At 6 of the clinic visits participants cannot take pain medications for 3 days before the visit. Participants cannot take part if participants have had a joint replacement surgery in participants knee. Participants cannot take part if participants have or have had diabetes. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions Studied
Interventions
- DRUG semaglutide 2.4 mg
- DRUG semaglutide 2.4 mg (placebo)
Study Locations (20)
California
- Anaheim Clinical Trials, LLC — Anaheim
- Stuart L. Silverman MD - A Medical Corporation — Beverly Hills
- Valley Research — Fresno
- Providence Medical Foundation — Fullerton
- Desert Oasis Hlthcr Med Group — Palm Springs
- Encompass Clinical Research_Spring Valley — Spring Valley
- Diablo Clinical Research, Inc. — Walnut Creek
Florida
- Clinical Research of Hollywood_Hollywood — Hollywood
- Westside Center For Clinical Research — Jacksonville
- Jacksonville Ctr For Clin Res — Jacksonville
- Well Pharma Medical Research Corp — Miami
- Renstar Medical Research — Ocala
- Clinical Trial Res Assoc,Inc — Plantation
Illinois
- Clinical Invest Special_Gurnee — Gurnee
- Evanston Premier Hlthcr Res — Skokie
- Clinical Invest Special_Gurnee — Wauconda
Alabama
- Baptist Health System — Montgomery
Arizona
- Ortho Arizona — Phoenix
Hawaii
- East West Medical Research Institute_Honolulu — Honolulu
Indiana
- MediSphere Medical RC — Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05064735
The ClinicalTrials.gov registry entry for NCT05064735 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which semaglutide 2.4 mg is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05064735 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05064735 about?
NCT05064735 is a clinical study titled "Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis". This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pai...
What is the current status of trial NCT05064735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 407 participants. The study started on 2021-10-01. Estimated completion is 2023-09-08.
What conditions does trial NCT05064735 study?
This clinical trial studies the following conditions: Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05064735?
The interventions under investigation include: semaglutide 2.4 mg (DRUG), semaglutide 2.4 mg (placebo) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05064735?
This trial is sponsored by Novo Nordisk A/S, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05064735 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.